Abstract
One of the pathophysiological mechanisms of the development of some mental diseases, including depressive disorders, is a decrease in the expression of brain-derived neurotrophic factor (BDNF), mainly in the limbic region and prefrontal cortex of the brain. Immunochemical screening of BDNF in biological fluids showed that the levels of this protein can be considered as a marker of predisposition to depression and a prognostic marker of the effectiveness of therapy. The use of modern technologies for the production of recombinant proteins makes it possible to develop highly standardized ELISA systems for the determination of this antigen in biological fluids. This paper describes a method for creating a test system for quantitative ELISA of brain-derived neurotrophic factor on the basis of recombinant protein BDNF and antibodies obtained as a result of immunization with recombinant BDNF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
